Latest Content

FDA approves Breztri Aerosphere for asthma, introducing the first single-inhaler triple-combination maintenance therapy for patients aged 12 and older.

In this exclusive video interview at Assembia 2026, Kim Plesnarski touches on how digital tools reshape patient access programs as real-time data and EMR integration drive more personalized, workflow-embedded support strategies.

Dr. Stella Vnook explains how US pricing regulations, such as MFN and the IRA, are forcing pharma companies to adjust strategies in international markets.

Ireland has built a track record of regulatory excellence that few regions have matched.

Experts convened for a panel discussing how tariffs and MFN policies are impacting drug pricing and what regulatory hurdles they face ahead of the midterms later this year.

Tommy Bramley, SVP of global consulting at Cencora, discusses how broadening acceptance of RWE has a broad impact on launch strategies.

In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to $2.3 billion, adding a first-in-class JAK2 inhibitor for blood cancers to its expanding oncology pipeline, the FDA approves a supplemental application for Johnson and Johnson's Caplyta backed by Phase III data showing a 63% reduction in relapse risk in adults with schizophrenia, and Pharmaceutical Executive speaks with Maher Masoud, CEO of MaxCyte, on moving cell and gene therapies toward commercial scale.

FDA approves Caplyta for relapse prevention in schizophrenia, adding long-term Phase III data showing a 63% reduction in relapse risk and reinforcing its role in sustained disease management.

Eli Lilly to acquire Ajax Therapeutics in up to $2.3B deal, adding a first-in-class Type II JAK2 inhibitor to strengthen its blood cancer pipeline.

Dr. Stella Vnook discusses how pricing transparency and VBC might have a more positive impact than MFN and other pricing regulations.

Accurate and reliable data is essential to provide leaders with the right information to power these systems.

FDA granted Compass Pathways with a rolling review for COMP360, a proprietary formulation of synthetic psilocybin, in treatment-resistant depression.

In today’s Pharmaceutical Executive Daily, the FDA issues a complete response letter to AbbVie for a biologics license application, Regeneron moves to lower patient costs tied to its newly approved gene therapy, and the FDA approves Otarmeni for OTOF-related hearing loss.